Hims & Hers Expects Customers to Return to Branded Weight Loss Drugs -- Market Talk

Dow Jones

Feb 25, 2025

1835 ET - Hims & Hers Health says it will stop offering compounded semaglutide, a version of the active ingredient in weight-loss drugs Wegovy and Ozempic, after the first quarter. The stoppage comes after the FDA last week determined that shortages of the drugs had been resolved. CEO Andrew Dudum says on a call with analysts that the company will begin notifying customers of the stop in the coming weeks. "I would suspect, you know, just being very direct, that a lot of those patients will try to go into the open market and try to secure a branded option in some form factor," he says, though he adds that the company will continue to offer other forms of weight-loss drugs on its platform. Shares fall 18% in after-hours trading. (connor.hart@wsj.com)

(END) Dow Jones Newswires

February 24, 2025 18:35 ET (23:35 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2514700458"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514700458\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514700458?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 07:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514700458","market":"sg","top_or_hot":-1,"title":"Hims & Hers Expects Customers to Return to Branded Weight Loss Drugs -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1835 ET - Hims &amp; Hers Health says it will stop offering compounded semaglutide, a version of the active ingredient in weight-loss drugs Wegovy and Ozempic, after the first quarter. The stoppage comes after the FDA last week determined that shortages of the drugs had been resolved. CEO Andrew Dudum says on a call with analysts that the company will begin notifying customers of the stop in the coming weeks. \"I would suspect, you know, just being very direct, that a lot of those patients will try to go into the open market and try to secure a branded option in some form factor,\" he says, though he adds that the company will continue to offer other forms of weight-loss drugs on its platform. Shares fall 18% in after-hours trading. (connor.hart@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2025 18:35 ET (23:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Expects Customers to Return to Branded Weight Loss Drugs -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Expects Customers to Return to Branded Weight Loss Drugs -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-25 07:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1835 ET - Hims &amp; Hers Health says it will stop offering compounded semaglutide, a version of the active ingredient in weight-loss drugs Wegovy and Ozempic, after the first quarter. The stoppage comes after the FDA last week determined that shortages of the drugs had been resolved. CEO Andrew Dudum says on a call with analysts that the company will begin notifying customers of the stop in the coming weeks. \"I would suspect, you know, just being very direct, that a lot of those patients will try to go into the open market and try to secure a branded option in some form factor,\" he says, though he adds that the company will continue to offer other forms of weight-loss drugs on its platform. Shares fall 18% in after-hours trading. (connor.hart@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2025 18:35 ET (23:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2514700458","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514700458","pubTimestamp":1740440100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1835 ET - Hims & Hers Health says it will stop offering compounded semaglutide, a version of the active ingredient in weight-loss drugs Wegovy and Ozempic, after the first quarter. The stoppage comes after the FDA last week determined that shortages of the drugs had been resolved. CEO Andrew Dudum says on a call with analysts that the company will begin notifying customers of the stop in the coming weeks. \"I would suspect, you know, just being very direct, that a lot of those patients will try to go into the open market and try to secure a branded option in some form factor,\" he says, though he adds that the company will continue to offer other forms of weight-loss drugs on its platform. Shares fall 18% in after-hours trading. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","BK4211":"区域性银行","CUBI":"Customers Bancorp Inc.","HIMS":"Hims & Hers Health Inc."},"translate_title":"Hims&Hers预计顾客将回归品牌减肥药——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUBI":1,"HIMS":0.9},"content_text":"1835 ET - Hims & Hers Health says it will stop offering compounded semaglutide, a version of the active ingredient in weight-loss drugs Wegovy and Ozempic, after the first quarter. The stoppage comes after the FDA last week determined that shortages of the drugs had been resolved. CEO Andrew Dudum says on a call with analysts that the company will begin notifying customers of the stop in the coming weeks. \"I would suspect, you know, just being very direct, that a lot of those patients will try to go into the open market and try to secure a branded option in some form factor,\" he says, though he adds that the company will continue to offer other forms of weight-loss drugs on its platform. Shares fall 18% in after-hours trading. (connor.hart@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2025 18:35 ET (23:35 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}